Cancer treatment is evolving rapidly, but one major challenge still remains — tumors constantly change. Traditional tissue biopsies and standard liquid biopsy methods often fail to capture these real-time changes, making it difficult to accurately identify the right patients, monitor treatment response, or detect emerging resistance early.
This whitepaper introduces OncoIncytes, an advanced AI-powered precision oncology platform designed to address these critical gaps. By combining single-cell circulating tumor cell (CTC) analysis, ctDNA profiling, transcriptomics, and proteomics from a single blood draw, OncoIncytes delivers a deeper and more dynamic understanding of tumor biology.
The paper explores how this integrated multi-omics approach can improve patient selection, monitor target expression in real time, identify resistant tumor clones earlier, and support the development of next-generation therapies like ADCs and bispecific ancttibodies.
If you are involved in oncology research, drug development, clinical trials, or precision medicine, this whitepaper provides valuable insights into how real-time tumor intelligence can help improve treatment decisions and clinical outcomes.
Download the full whitepaper to explore the future of precision oncology.